Cleveland Clinic | Strategic Alliance Partners

James Stevenson, MD, discusses the importance of early screening in lung cancer.

Jacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Pradnya D. Patil, MD, FACP, discusses recent developments with targeted therapies in lung cancer.

James Stevenson, MD, discusses ongoing research efforts that are generating excitement in extensive-stage small cell lung cancer.

Pauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.

Jacob G. Scott, MD, DPhil, discusses the rationale to evaluate genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

G. Thomas Budd, MD, discussed the promise of tailored treatment approaches in HER2-positive breast cancer, the utility of the combination of fixed-dose trastuzumab, pertuzumab, and hyaluronidase-zzxf via subcutaneous administration, and how sequencing could be further affected by drug development.

Halle Moore, MD, discusses the data that support the use of CDK4/6 inhibitors plus endocrine therapy in HR-positive, HER2-negative breast cancer, how to select between available CDK4/6 inhibitors in the metastatic setting, and the current state of this treatment approach for patients with early-stage disease.

Eric Klein, MD, discusses the promise of VERU-111 in patients with metastatic CRPC and other research efforts that are generating excitement in the paradigm.

Nathan A. Pennell, MD, PhD, discusses the importance of understanding the cost-effectiveness of osimertinib in non–small cell lung cancer.

For patients with myelofibrosis who have platelets counts of less than 50,000, pacritinib represents a potential therapeutic option that can fill a need that has been unmet with other approved JAK inhibitors, such as ruxolitinib and fedratinib.

Eric Klein, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Erin Murphy, MD, discusses remaining questions with stereotactic body radiotherapy in pediatric sarcoma.

Erin Murphy, MD, discusses the clinical implications of pazopanib plus stereotactic body radiotherapy in pediatric sarcoma.

Robert M. Dean, MD, discusses the potential role for consolidative CAR T-cell therapy in mantle cell lymphoma.

Eric Klein, MD, discusses safety data with VERU-111 from a phase 2 trial that enrolled patients with metastatic castration-resistant prostate cancer that was presented during the 2021 Genitourinary Cancers Symposium.

Erin Murphy, MD, discusses the utility of pazopanib plus stereotactic body radiation therapy in pediatric sarcoma.

Halle Moore, MD, discusses the use of preventive anastrozole versus tamoxifen in ductal carcinoma in situ.

Shilpa Gupta, MD, discusses the need to develop biomarkers of lack of response to immunotherapy in urothelial carcinoma.

Bryon Lee, MD, PhD, discusses recent advances in surgical technique, approach, and perioperative care have made radical cystectomy significantly less morbid for patients with muscle invasive bladder cancer.

Omar Mian, MD, PhD, discusses selective bladder preservation in patients with muscle-invasive bladder cancer, biomarkers of response, and the utilization of hypofractionated radiation vs traditional approaches in this population.

Shilpa Gupta, MD, discusses ongoing research with immunotherapy in bladder cancer, where research efforts should focus with regard to biomarkers, and other emerging agents that might move the needle forward.

For the population of hospitalized patients with cancer, many of whom who have not contracted the disease, COVID-19 has real, immediate consequences; the pandemic has radically altered their end-of-life care.

December 23, 2020 - Pacritinib, when delivered at a twice-daily dose of 200 mg, was found to demonstrate clinical activity with an acceptable toxicity profile in patients with myelofibrosis and severe thrombocytopenia.

Faculty from a recent Institutional Perspectives in Cancer webinar on bladder cancer hosted by Cleveland Clinic share updates in the management of metastatic urothelial carcinoma, as well as robotic cystectomy and bladder preservation approaches in muscle-invasive bladder cancer.

Brian T. Hill, MD, PhD, discusses ​the safety profiles of BTK inhibitors in mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses ​the safety profiles of BTK inhibitors in mantle cell lymphoma.

Allison Winter, MD, discusses emerging agents in chronic lymphocytic leukemia.

Brian T. Hill, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Allison Winter, MD, hematologist/medical oncologist, Cleveland Clinic, discusses the role of frontline targeted therapies in chronic lymphocytic leukemia.